Selzentry (Maraviroc, Celsentri)
| Brand Name: |
Selzentry |
| Generic Name: |
Maraviroc, MVC |
| Adult Single Dose: |
150 mg twice daily; OR 300 mg twice daily; OR 600 mg twice daily based on coadministered drugs |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
Entry inhibitor |
|
|
|
The Basics
- An Overview of Selzentry (Maraviroc, Celsentri) (September 13, 2012)
From AIDSinfo
- Maraviroc (Selzentry, Celsentri) (June 21, 2012)
To read PDF, click here.
From AIDS InfoNet
- Selzentry (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Selzentry (Maraviroc, Celsentri) Patient Information and Drug Warnings (PDF) (November 2011)
From ViiV Healthcare
- FAQs About Selzentry (Maraviroc, Celsentri) (October 19, 2009)
From The Body's "Ask the Experts" Forums
- A Revolutionary New Way to Fight HIV/AIDS: CCR5 Inhibitors (September 2008)
Find out more about Selzentry in this special report.
From TheBody.com
- A New Way to Fight HIV: CCR5 Inhibitors (April 30, 2008)
An interview with David Hardy, M.D.
From TheBody.com
- Selzentry (Maraviroc) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- FDA Approves Pfizer's Antiretroviral Maraviroc (August 7, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Approval of Maraviroc (August 6, 2007)
From U.S. Food and Drug Administration
- The Basics on Maraviroc: An Interview With Joel Gallant, M.D., M.P.H. (August 6, 2007)
From TheBody.com
- CCR5: A Genetic Mistake Makes Good (March 2004)
From amfAR, The Foundation for AIDS Research
|
Advertisement
|
Email
Glossary
